Global: WHO narrows down second-line ARV options

As developing countries scale up their antiretroviral (ARV) treatment programmes, more and more people living with HIV are expected to develop resistance to their drug regimens and will need second-line medicines. Many second-line drugs are either unavailable or prohibitively expensive in developing countries, and doctors often lack experience or knowledge of what combination of second-line ARVs to prescribe.